New drug cocktail aims to shrink tough lung cancers

NCT ID NCT07698054

Not yet recruiting Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedule of oral and intravenous chemotherapy drugs. The study measures how many patients experience significant tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: toripalimab, etoposide, carboplatin, temozolomide, anlotinib
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer who have already tried other therapies.
What could go wrong: This is an early-phase trial with a small number of participants. The treatment may not work for everyone and could cause significant side effects from chemotherapy and immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BAYESIAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BAYESIAN METRONOMIC CHEMOTHERAPY SCLC,EXTENSIVE STAGE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.